Skip to content

Study to find out the effect of Camylofin 50 mg and Paracetamol 325mg drug in patients with acute colicky abdominal pain

An investigator initiated prospective single arm open-label study to evaluate effectiveness of Camylofin 50 mg and Paracetamol 325mg in patients with acute colicky abdominal pain - ACAP Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061405
Enrollment
100
Registered
2024-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K318- Other specified diseases of stomach and duodenum

Interventions

Intervention1: NA: NA

Sponsors

Abbott Healthcare Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Female subjects aged 18 65 years Patients attending OPD with acute colicky abdominal pain and having at least one episode of colicky pain within 24 hours prior to the visit Non complicated cases of acute colicky abdominal pain may be confirmed by imaging tests such as Ultrasound Sonography USG performed prior to the treatment initiation to ensure no complicated cases get recruited as perwill be performed at the discretion of the investigator Patient willing to provide written informed consent to will be enrolled in the study

Exclusion criteria

Exclusion criteria: Patients with history of hypersensitivity to the study drugs any of study drugs ingredients Patients who had undergone coronary artery bypass graft surgery with epilepsy or inflammatory bowel disease will be excluded Patients with chronic abdominal pain such as Celiac disease lactose intolerance ulcerative colitis and Crohns disease Patients who may have narrow angle glaucoma mechanical stenosis Pregnancy and lactation Urinary retention Mega colon GI hemorrhage Tachyarrhythmia Porphyria Patients with any other conditions or diseases that investigator considers as ineligible to enroll in the study based on approved prescribing information

Design outcomes

Primary

MeasureTime frame
Percentage change in the mean intensity of pain based on the 100mm VAS score from baseline to EOSTimepoint: Percentage change in the mean intensity of pain based on the 100mm VAS score from baseline to EOS

Secondary

MeasureTime frame
To assess how much time it takes on average for people to feel relief from pain by looking at a ten point reduction in the pain intensity score on the visual analogue scaleTimepoint: To assess how much time it takes on average for people to feel relief from pain by looking at a ten point reduction in the pain intensity score on the visual analogue scale

Countries

India

Contacts

Public ContactDr Chandravati

Krishna Medical Center

drchandravati@gmail.com9839011146

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026